These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 18050213

  • 1. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
    Yee CS, Farewell V, Isenberg DA, Rahman A, Teh LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, D'Cruz D, Khamashta MA, Maddison P, Gordon C.
    Arthritis Rheum; 2007 Dec; 56(12):4113-9. PubMed ID: 18050213
    [Abstract] [Full Text] [Related]

  • 2. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.
    Nasiri S, Karimifar M, Bonakdar ZS, Salesi M.
    Rheumatol Int; 2010 Nov; 30(12):1605-9. PubMed ID: 19809816
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally.
    Yee CS, Gordon C, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y, Rahman A, Prabu A, Akil M, McHugh N, Edwards CJ, D'Cruz D, Khamashta MA, Farewell VT.
    Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1623-1630. PubMed ID: 33787088
    [Abstract] [Full Text] [Related]

  • 4. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A, Barr SG, Magder LS, Petri M.
    Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
    [Abstract] [Full Text] [Related]

  • 5. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 6. Serum and urine interleukin-17A levels as biomarkers of disease activity in systemic lupus erythematosus.
    Nordin F, Shaharir SS, Abdul Wahab A, Mustafar R, Abdul Gafor AH, Mohamed Said MS, Rajalingham S, Shah SA.
    Int J Rheum Dis; 2019 Aug; 22(8):1419-1426. PubMed ID: 31179646
    [Abstract] [Full Text] [Related]

  • 7. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.
    Lim KL, Jones AC, Brown NS, Powell RJ.
    Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.
    Ward MM, Marx AS, Barry NN.
    J Rheumatol; 2000 Mar; 27(3):664-70. PubMed ID: 10743805
    [Abstract] [Full Text] [Related]

  • 9. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.
    Ho A, Magder LS, Barr SG, Petri M.
    Arthritis Rheum; 2001 Oct; 44(10):2342-9. PubMed ID: 11665975
    [Abstract] [Full Text] [Related]

  • 10. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus.
    Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA.
    Ann Rheum Dis; 1996 Oct; 55(10):756-60. PubMed ID: 8984942
    [Abstract] [Full Text] [Related]

  • 11. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000.
    Yee CS, Isenberg DA, Prabu A, Sokoll K, Teh LS, Rahman A, Bruce IN, Griffiths B, Akil M, McHugh N, D'Cruz D, Khamashta MA, Maddison P, Zoma A, Gordon C.
    Ann Rheum Dis; 2008 Jun; 67(6):873-6. PubMed ID: 17519277
    [Abstract] [Full Text] [Related]

  • 12. Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study.
    Fatemi A, Raeisi A, Sayedbonakdar Z, Smiley A.
    Clin Rheumatol; 2018 Apr; 37(4):955-962. PubMed ID: 29256112
    [Abstract] [Full Text] [Related]

  • 13. The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus.
    Marks SD, Pilkington C, Woo P, Dillon MJ.
    Rheumatology (Oxford); 2004 Sep; 43(9):1186-9. PubMed ID: 15226518
    [Abstract] [Full Text] [Related]

  • 14. Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: correlations with clinical manifestations and disease activity.
    Emad Y, Gheita T, Darweesh H, Klooster P, Gamal R, Fathi H, El-Shaarawy N, Gamil M, Hawass M, El-Refai RM, Al-Hanafi H, Abd-Ellatif S, Ismail A, Rasker J.
    Reumatismo; 2018 Jul 06; 70(2):85-91. PubMed ID: 29976042
    [Abstract] [Full Text] [Related]

  • 15. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity.
    Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, Rahman A, Bruce IN, Griffiths B, Akil M, McHugh N, D'Cruz D, Khamashta MA, Bowman S, Maddison P, Zoma A, Allen E, Gordon C, British Isles Lupus Assessment Group.
    Arthritis Rheum; 2006 Oct 06; 54(10):3300-5. PubMed ID: 17009266
    [Abstract] [Full Text] [Related]

  • 16. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
    Závada J, Uher M, Svobodová R, Olejárová M, Hušáková M, Ciferská H, Hulejová H, Tomčík M, Šenolt L, Vencovský J.
    Arthritis Res Ther; 2015 Nov 25; 17():341. PubMed ID: 26608564
    [Abstract] [Full Text] [Related]

  • 17. Urine neopterin: a new parameter for serial monitoring of disease activity in patients with systemic lupus erythematosus.
    Lim KL, Muir K, Powell RJ.
    Ann Rheum Dis; 1994 Nov 25; 53(11):743-8. PubMed ID: 7826135
    [Abstract] [Full Text] [Related]

  • 18. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation.
    Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, Kalunian K, Liang MH, Maddison P, Nived O.
    J Rheumatol; 1994 Aug 25; 21(8):1468-71. PubMed ID: 7983648
    [Abstract] [Full Text] [Related]

  • 19. Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in Systemic Lupus Erythematosus.
    Mora C, Medina-Rosas J, Santos AM, Jaimes DA, Arbeláez AM, Romero C, Cortes A, Londono J.
    J Rheumatol; 2016 Sep 25; 43(9):1657-64. PubMed ID: 27134246
    [Abstract] [Full Text] [Related]

  • 20. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
    Wais T, Fierz W, Stoll T, Villiger PM.
    J Rheumatol; 2003 Oct 25; 30(10):2133-9. PubMed ID: 14528506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.